The purpose of this study is to determine predictors of response to pioglitazone, an
anti-diabetic medication. The investigators know from randomized clinical trials that some
30% of patients do not respond to this type of medication. There is presently no way to
identify this group of patients leading to unnecessary drug exposure and medication costs.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)